|Other names||Thrombocytopaenia, thrombopenia|
|Blood under a microscope showing thrombocytopenia|
|Symptoms||Purple bruises, small red dots in the skin, bleeding gums|
|Causes||Bone marrow not making enough, increased destruction, spleen holding too many|
|Diagnostic method||Platelets < 150 x 109/L|
|Treatment||None, immunosuppressants, platelet transfusion, surgical removal of the spleen|
Thrombocytopenia is a low levels of platelets (thrombocytes) in the blood. Symptoms may include bleeding, including within the body, into the skin, or externally such as from the gums. Bleeding into the skin may result in purpura (purple bruises) or petechiae (small red dots).
Low platelets may occur due to insufficient production, increased destruction, or the spleen holding on to too many. Insufficient production may occur due to leukemia, aplastic anemia, certain chemicals or medications, alcohol, viral infections, and genetic conditions. Increased destruction may occur due to immune thrombocytopenia (ITP), certain medications, infections, surgery, pregnancy, thrombotic thrombocytopenic purpura (TTP) and disseminated intravascular coagulation (DIC). The spleen may hold on to too many when it is enlarged. In adults there are normally 150 to 450 x 109 platelets per L (150,000 to 450,000 per mm3) of blood with values below that defined as thrombocytopenia.
Treatment depends on the cause. Mild cases may not require specific treatment. In severe disease corticosteroids, rituximab, or eltrombopag may be used. When platelets are below 20 x 109 per L a platelet transfusion may be recommended. Surgical removal of the spleen may be used if medications are not effective. The condition is relatively common, with about half of people in the intensive care unit having the condition.
Signs and symptoms
Thrombocytopenia usually has no symptoms and is picked up on a routine complete blood count. Some individuals with thrombocytopenia may experience external bleeding such as nosebleeds, or bleeding gums. Some women may have heavier or longer periods or breakthrough bleeding. Bruising, particularly purpura in the forearms and petechiae in the feet, legs, and mucous membranes, may be caused by spontaneous bleeding under the skin.
Eliciting a full medical history is vital to ensure the low platelet count is not secondary to another disorder. Ensuring that the other blood cell types, such as red blood cells and white blood cells are not also suppressed, is also important. Painless, round, and pinpoint (1 to 3 mm in diameter) petechiae usually appear and fade, and sometimes group to form ecchymoses. Larger than petechiae, ecchymoses are purple, blue, or yellow-green areas of skin that vary in size and shape. They can occur anywhere on the body.
A person with this disease may also complain of malaise, fatigue, and general weakness (with or without accompanying blood loss). Acquired thrombocytopenia may be associated with the use of certain drugs. Inspection typically reveals evidence of bleeding (petechiae or ecchymoses), along with slow, continuous bleeding from any injuries or wounds. Adults may have large, blood-filled bullae in the mouth. If the person's platelet count is between 30,000 and 50,000/mm3, bruising with minor trauma may be expected; if it is between 15,000 and 30,000/mm3, spontaneous bruising will be seen (mostly on the arms and legs).
Thrombocytopenia can be inherited or acquired.
Abnormally low platelet production may be caused by:
- Dehydration, vitamin B12 or folic acid deficiency
- Leukemia, myelodysplastic syndrome, or aplastic anemia
- Decreased production of thrombopoietin by the liver in liver failure
- Sepsis, systemic viral or bacterial infection
- Genetic syndromes
- ACTN1-related thrombocytopenia
- Alport syndrome
- Amegakaryocytic thrombocytopenia with radio-ulnar synostosis
- ANKRD26 related thrombocytopenia
- Autosomal dominant thrombocytopenia
- Bernard–Soulier syndrome (associated with large platelets)
- Congenital amegakaryocytic thrombocytopenia
- Congenital amegakaryocytic thrombocytopenia and radioulnar synostosis
- CYCS-related thrombocytopenia
- ETV6 related thrombocytopenia
- Fanconi anemia
- Filaminopathies A
- FYB related thrombocytopenia
- Glanzmann's thrombasthenia
- GNE myopathy with congenital thrombocytopenia
- Gray platelet syndrome
- Macrothrombocytopenia and hearing loss
- May–Hegglin anomaly
- MYH9-related disease
- PRKACG-related thrombocytopenia
- Paris-Trousseau thrombocytopenia/Jacobsen syndrome
- SLFN14-related thrombocytopenia
- Stormorken syndrome
- TRPM7-related thrombocytopenia
- Thrombocytopenia absent radius syndrome
- Tropomyosin 4-related thrombocytopenia
- TUBB1-related thrombocytopenia
- Upshaw–Schulman syndrome
- Wiskott–Aldrich syndrome
- X-linked thrombocytopenia
- X-linked thrombocytopenia with thalassemia
Abnormally high rates of platelet destruction may be due to immune or nonimmune conditions, including:
- Immune thrombocytopenic purpura
- Thrombotic thrombocytopenic purpura
- Hemolytic–uremic syndrome
- Disseminated intravascular coagulation
- Paroxysmal nocturnal hemoglobinuria
- Antiphospholipid syndrome
- Systemic lupus erythematosus
- Post-transfusion purpura
- Neonatal alloimmune thrombocytopenia
- Dengue fever
- Gaucher's disease
- Zika virus
These medications can induce thrombocytopenia through direct myelosuppression:
- Valproic acid
- H2 blockers and proton-pump inhibitors
- Lab error, possibly due to the anticoagulant EDTA in CBC specimen tubes; a citrated platelet count is a useful follow-up study
- Niacin toxicity
- Lyme disease
- Thrombocytapheresis (also called plateletpheresis)
- Niemann–Pick disease
Laboratory tests for thrombocytopenia might include full blood count, liver enzymes, kidney function, vitamin B12 levels, folic acid levels, erythrocyte sedimentation rate, and peripheral blood smear. If the cause for the low platelet count remains unclear, a bone marrow biopsy is usually recommended to differentiate cases of decreased platelet production from cases of peripheral platelet destruction.
Thrombocytopenia in hospitalized alcoholics may be caused by spleen enlargement, folate deficiency, and most frequently, the direct toxic effect of alcohol on production, survival time, and function of platelets. Platelet count begins to rise after 2 to 5 days' abstinence from alcohol. The condition is generally benign, and clinically significant hemorrhage is rare.
In severe thrombocytopenia, a bone marrow study can determine the number, size, and maturity of the megakaryocytes. This information may identify ineffective platelet production as the cause of thrombocytopenia and rule out a malignant disease process at the same time.
Thrombocytopenia can be contrasted with thrombocythemia and thrombocytosis, a high level of platelets in the blood. Thrombocythemia when the cause is unknown; thrombocytosis when the cause is known.
Treatment is guided by the severity and specific cause of the disease. Treatment focuses on eliminating the underlying problem, whether that means discontinuing drugs suspected to cause it or treating underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist. Corticosteroids may be used to increase platelet production. Lithium carbonate or folate may also be used to stimulate platelet production in the bone marrow.
Thrombotic thrombocytopenic purpura
Treatment of thrombotic thrombocytopenic purpura (TTP) is a medical emergency, since the associated hemolytic anemia and platelet activation can lead to kidney failure and changes in the level of consciousness. Treatment of TTP was revolutionized in the 1980s with the application of plasmapheresis. According to the Furlan-Tsai hypothesis, this treatment works by removing antibodies against the von Willebrand factor-cleaving protease ADAMTS-13. The plasmapheresis procedure also adds active ADAMTS-13 protease proteins to the patient, restoring a normal level of von Willebrand factor multimers. Patients with persistent antibodies against ADAMTS-13 do not always manifest TTP, and these antibodies alone are not sufficient to explain how plasmapheresis treats TTP.
Immune thrombocytopenic purpura
Many cases of immune thrombocytopenic purpura (ITP) also known as idiopathic thrombocytopenic purpura, can be left untreated, and spontaneous remission (especially in children) is not uncommon. However, counts under 50,000 are usually monitored with regular blood tests, and those with counts under 10,000 are usually treated, as the risk of serious spontaneous bleeding is high with such low platelet counts. Any patient experiencing severe bleeding symptoms is also usually treated. The threshold for treating ITP has decreased since the 1990s; hematologists recognize that patients rarely spontaneously bleed with platelet counts greater than 10,000, although exceptions to this observation have been documented.
Thrombopoetin analogues have been tested extensively for the treatment of ITP. These agents had previously shown promise, but had been found to stimulate antibodies against endogenous thrombopoietin or lead to thrombosis. Romiplostim (trade name Nplate, formerly AMG 531) was found to be safe and effective for the treatment of ITP in refractory patients, especially those who relapsed following splenectomy.
Discontinuation of heparin is critical in a case of heparin-induced thrombocytopenia (HIT). Beyond that, however, clinicians generally treat to avoid thrombosis. Treatment may include a direct thrombin inhibitor, such as lepirudin or argatroban. Other blood thinners sometimes used in this setting include bivalirudin and fondaparinux. Platelet transfusions are not routinely used to treat HIT because thrombosis, not bleeding, is the primary problem. Warfarin is not recommended until platelets have normalized.
Congenital amegakaryocytic thrombocytopenia
Bone marrow/stem cell transplants are the only known cures for this genetic disease. Frequent platelet transfusions are required to keep the patient from bleeding to death before the transplant can be performed, although this is not always the case.
Human induced pluripotent stem cell-derived platelets
Human induced pluripotent stem cell-derived platelets is a technology currently being researched by the private sector, in association with the Biomedical Advanced Research and Development Authority and the U.S. Department of Health and Human Services, that would create platelets outside the human body.
Thrombocytopenia affects a few newborns, and its prevalence in neonatal intensive care units is high. Normally, it is mild and resolves without consequences. Most cases affect preterm birth infants and result from placental insufficiency and/or fetal hypoxia. Other causes, such as alloimmunity, genetics, autoimmunity, and infection, are less frequent.
Thrombocytopenia that starts after the first 72 hours since birth is often the result of underlying sepsis or necrotizing enterocolitis. In the case of infection, PCR tests may be useful for rapid pathogen identification and detection of antibiotic resistance genes. Possible pathogens include viruses (e.g. cytomegalovirus, rubella virus, HIV), bacteria (e.g. Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, Listeria monocytogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Yersinia enterocolitica), fungi (e.g. Candida spp.), and Toxoplasma gondii. The severity of thrombocytopenia may be correlated with pathogen type; some research indicates that the most severe cases are related to fungal or Gram-negative bacterial infection. The pathogen may be transmitted during or before birth, by breast feeding, or during transfusion. Interleukin-11 is being investigated as a drug for managing thrombocytopenia, especially in cases of sepsis or necrotizing enterocolitis (NEC).
- "Thrombocytopenia". www.nhlbi.nih.gov. Retrieved 22 November 2020.
- Deutschman, Clifford S.; Neligan, Patrick J. (2010). Evidence-based Practice of Critical Care. Elsevier Health Sciences. ISBN 978-1416054764. Retrieved 2015-04-30.
- Lee, EJ; Lee, AI (December 2016). "Thrombocytopenia". Primary care. 43 (4): 543–557. doi:10.1016/j.pop.2016.07.008. PMID 27866576.
- Bhatia, M.P.S. "B.E. Project on Platlet Count Using Image Processing Techniques" (PDF). BTP_Report. Retrieved 30 November 2014.
- Houghton, Andrew R.; Gray, David (2010). Chamberlain's Symptoms and Signs in Clinical Medicine 13th Edition, An Introduction to Medical Diagnosis. CRC Press. ISBN 9780340974254. Retrieved 2015-05-01.
- Interpreting Signs and Symptoms. Lippincott Williams & Wilkins. 2007. p. 293. ISBN 9781582556680.
- Rosdahl, Caroline Bunker; Kowalski, Mary T. (2008). Textbook of Basic Nursing. Lippincott Williams & Wilkins. ISBN 9780781765213. Retrieved 2015-05-01.
- "What Causes Thrombocytopenia?". National Heart, Lung, and Blood Institute. Retrieved 4 December 2014.
- Fiebach, Nicholas H.; Barker, Lee Randol; Burton, John Russell; Zieve, Philip D. (2007). Principles of Ambulatory Medicine. Lippincott Williams & Wilkins. ISBN 9780781762274. Retrieved 2015-04-30.
- Almazni I, Stapley R, Morgan NV (2019) Inherited Thrombocytopenia: Update on genes and genetic variants which may be associated With bleeding. Front Cardiovasc Med
- Rodak, Bernadette F.; Fritsma, George A.; Keohane, Elaine (2013). Hematology: Clinical Principles and Applications. Elsevier Health Sciences. ISBN 9780323292696. Retrieved 2015-04-30.
- Gresele, Paolo; Fuster, Valentin; Lopez, Jose A.; Page, Clive P.; Vermylen, Jos (2007). Platelets in Hematologic and Cardiovascular Disorders: A Clinical Handbook. Cambridge University Press. ISBN 9781139468763. Retrieved 2015-04-30.
- Tan, GC; Stalling, M; Dennis, G; Nunez, M; Kahwash, SB (2016). "Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature". Case Reports in Hematology. 2016: 1–4. doi:10.1155/2016/3036476. PMC 5164902. PMID 28044112.
- Waldmann, Carl; Soni, Neil; Rhodes, Andrew (2008). Oxford Desk Reference: Critical Care. Oxford University Press. ISBN 9780199229581. Retrieved 2015-05-01.
- Dart, Richard C. (2004). Medical Toxicology. Lippincott Williams & Wilkins. ISBN 9780781728454. Retrieved 2015-05-01.
- Greer, John P.; Arber, Daniel A.; Glader, Bertil; List, Alan F.; Means, Robert T.; Paraskevas, Frixos; Rodgers, George M. (2013). Wintrobe's Clinical Hematology. Lippincott Williams & Wilkins. ISBN 9781469846224. Retrieved 2015-05-01.
- "Niemann-Pick disease". Genetics Home Reference.
- "How Is Thrombocytopenia Diagnosed? - NHLBI, NIH". www.nhlbi.nih.gov. Retrieved 2015-05-19.
- Lieber, Charles S. (2012). Medical and Nutritional Complications of Alcoholism: Mechanisms and Management. Springer Science & Business Media. ISBN 9781461533207.
- Hillyer, Christopher D.; Abrams, Charles S.; Shaz, Beth H.; Roshal, Mikhail; Zimring, James C.; Abshire, Thomas C. (2009). Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Elsevier. ISBN 9780080922300. Retrieved 2015-05-01.
- Schafer AI (March 2004). "Thrombocytosis". N. Engl. J. Med. 350 (12): 1211–9. doi:10.1056/NEJMra035363. PMID 15028825.
- "Thrombocythemia and Thrombocytosis | NHLBI, NIH". www.nhlbi.nih.gov. Retrieved 5 August 2020.
- Lawrence, Peter F.; Bell, Richard M.; Dayton, Merril T. (2012-10-31). Essentials of General Surgery. Lippincott Williams & Wilkins. ISBN 9780781784955.
- Estcourt, Lise J; Malouf, Reem; Hopewell, Sally; Doree, Carolyn; Van Veen, Joost (2018-04-30). Cochrane Haematological Malignancies Group (ed.). "Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia". Cochrane Database of Systematic Reviews. 4: CD011980. doi:10.1002/14651858.CD011980.pub3. PMC 5957267. PMID 29709077.
- Chapman, Kent; Seldon, Michael; Richards, Ross (2012). "Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13". Seminars in Thrombosis and Hemostasis. 38 (1): 47–54. doi:10.1055/s-0031-1300951. PMID 22314603.
- "How Is Thrombotic Thrombocytopenic Purpura Treated? - NHLBI, NIH". www.nhlbi.nih.gov. Retrieved 2015-05-20.
- Thrombocytopenic Purpura: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyPaper. ScholarlyEditions. 2013-07-22. ISBN 9781481662420.
- "Idiopathic thrombocytopenic purpura (ITP): MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2015-05-20.
- "Nplate (romiplostim) for subcutaneous injection". www.fda.gov. Retrieved 2015-05-02.
- Warkentin, Theodore E.; Greinacher, Andreas (2007-07-23). Heparin-Induced Thrombocytopenia. CRC Press. ISBN 9781439826423.
- Ahmed, I; Majeed, A; Powell, R (2007). "Heparin induced thrombocytopenia: diagnosis and management update". Postgraduate Medical Journal. 83 (983): 575–582. doi:10.1136/pgmj.2007.059188. ISSN 0032-5473. PMC 2600013. PMID 17823223.
- Smit-Sibinga, C. Th (2010-05-10). Neonatology and Blood Transfusion. Springer Science & Business Media. ISBN 9780387236001.
- Clark, Douglas (2019-10-02). "New technology may aid emergency preparedness". Homeland Preparedness News. Retrieved 2019-10-23.
- Roberts, I; Murray, N. A. (2003). "Neonatal thrombocytopenia: causes and management". Archives of Disease in Childhood: Fetal and Neonatal Edition. 88 (5): F359–64. doi:10.1136/fn.88.5.F359. ISSN 1468-2052. PMC 1721612. PMID 12937037.
- Guida, JD; Kunig, AM; Leef, KH; McKenzie, SE; Paul, DA (2003). "Platelet count and sepsis in very low birth-weight neonates: is there an organism-specific response?". Pediatrics. 111 (6 Pt 1): 1411–15. doi:10.1542/peds.111.6.1411. PMID 12777561.
- Pacifico, L; Chiesa, C; Mirabella, S; Panero, A; Midulla, M (1987). "Early-onset Pseudomonas aeruginosa sepsis and Yersinia enterocolitica neonatal infection: a unique combination in a preterm infant". European Journal of Pediatrics. 146 (2): 192–93. doi:10.1007/BF02343233. PMID 3569360. S2CID 20198866.
- Rempen, A; Martius, J; Hartmann, AA; Wecker, I (1987). "Transmission rate of Ureaplasma urealyticum, Mycoplasma spp., Gardnerella vaginalis, B-streptococci, Candida spp. and Chlamydia trachomatis from the mother to the newborn". Archives of Gynecology and Obstetrics. 241 (3): 165–70. doi:10.1007/BF00931313. PMID 3324978. S2CID 11251976.
- Olver, WJ; Bond, DW; Boswell, TC; Watkin, SL (2000). "Neonatal group B streptococcal disease associated with infected breast milk". Archives of Disease in Childhood: Fetal and Neonatal Edition. 83 (1): F48–49. doi:10.1136/fn.83.1.F48. PMC 1721104. PMID 10873172.
- Kotiw, M; Zhang, GW; Daggard, G; Reiss-Levy, E; Tapsall, JW; Numa, A (2003). "Late-onset and recurrent neonatal Group B streptococcal disease associated with breast-milk transmission". Pediatric and Developmental Pathology. 6 (3): 251–56. doi:10.1007/s10024-001-0276-y. PMID 12687430. S2CID 20696142.
- Gastelum, DT; Dassey, D; Mascola, L; Yasuda, LM (2005). "Transmission of community-associated methicillin-resistant Staphylococcus aureus from breast milk in the neonatal intensive care unit". The Pediatric Infectious Disease Journal. 24 (12): 1122–24. doi:10.1097/01.inf.0000189983.71585.30. PMID 16371885.
- Jagielski, Marek; Rastawicki, Waldemar; Kałużewski, Stanisław; Gierczyński, Rafał (2007). "Jersinioza – niedoceniana choroba zakaźna" [Yersiniosis – unappreciated infectious diseases] (PDF). Przegl Epidemiol (in Polish). 56 (1): 57–64. PMID 12150068. Archived from the original (PDF) on 2011-10-03. Retrieved 2011-04-10.CS1 maint: unrecognized language (link)
|Scholia has a topic profile for [[:toolforge:scholia/topic/Lua error in Module:WikidataIB at line 2818: attempt to index field 'wikibase' (a nil value).|Thrombocytopenia]].|